Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (3280)	6/11/1999 9:37:00 AM
From: BDR	Read Replies (1) \| Respond to of 10280

Things people are saying about the pharmaceutical industry, some favorable for SEPR, some not: labpuppy.com 6/10/99 Salomon Smith Barney also cut the pharmaceutical sector from an over-weight to a market-weight due to slowing earnings growth for the sector (versus rebounding earnings growth for the S&P), potential healthcare reform, weak new product pipelines and a number of big products going off patent in the near future. <As has often been stated on this thread SEPR's patented ICEs should be a plus in that environment> 6/9/99 From Amgen investor conference: Management made an interesting quote - This is the best time to in-license products as biotechs have many products in clinical development and are unable to gain financing (thus the biotechs are forced to license away their valuable products). <Was SEPR "forced" to license Zytec in Europe for "peanuts"?>